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Abstract
Background: Vascular endothelial growth factor (VEGF) is a major mediator of angiogenesis involving in
carcinogenesis, including lung cancer. We hypothesized that VEGF polymorphisms may affect survival outcomes
among locally advanced non-small cell lung cancer (LA-NSCLC) patients.
Methods: We genotyped three potentially functional VEGF variants [-460 T > C (rs833061), -634 G > C (rs2010963),
and +936 C > T (rs3025039)] and estimated haplotypes in 124 Caucasian patients with LA-NSCLC treated with
definitive radiotherapy. We used Kaplan-Meier log-rank tests, and Cox proportional hazard models to evaluate the
association between VEGF variants and overall survival (OS).
Results: Gender, Karnofsky’s performance scores (KPS) and clinical stage seemed to influence the OS. The variant C
genotypes were independently associated with significantly improved OS (CT+CC vs. TT: adjusted hazard ratio
[HR] = 0.58; 95% confidence interval [CI] = 0.37-0.92, P = 0.022), compared with the VEGF -460 TT genotype.
Conclusions: Our study suggests that VEGF -460 C genotypes may be associated with a better survival of
LA-NSCLC patients after chemoradiotherapy. Large studies are needed to confirm our findings.
Background
Non-small cell lung cancer (NSCLC) accounts for 89%
of all lung cancer, and 30% of NSCLC patients present
with locally-advanced unresectable tumors (unresectable
stage IIIa and IIIb) [1]. Radiotherapy combined with
chemotherapy, either sequentially or concurrently, is the
standard treatment regimen for these patients, which,
however, have resulted in unsatisfactory prognosis, with
a 5-year survival rate of about 10-15% [1], and a median
survival time (MST) of 16-18 months [2,3]. There has
been a persistent interest in search for readily accessible
molecular markers that may provide therapeutic benefits
by predicting clinical outcomes of these locally advanced
NSCLC (LA-NSCLC) on an individual basis.
Angiogenesis is an essential process in the develop-
ment, growth, and metastasis of malignant tumors
including lung cancer [4]. Vascular endothelial growth
factor (VEGF) is one of the most potent and predomi-
nant mediators of angiogenesis, which stimulate vascular
endothelial cell growth, survival, and proliferation.
Recent investigation has further revealed that VEGF acts
as a mitogenic and survival signal for the tumor cell
itself, indicating a broader range of tumor-promoting
effects. Therefore, VEGF stands as a good candidate for
prognostic biomarkers in cancer patients. Indeed, most
tumors produce VEGF, whereas inhibition of the VEGF
signaling significantly inhibits tumor growth in vivo [5].
In NSCLC, it has been found that a high expression of
VEGF protein or mRNA was associated with increased
tumor angiogenesis, early tumor relapse and reduced
survival time [6-8]. A recent report further linked some
functional VEGF polymorphisms with prognosis of early
stage (stage I and II) NSCLC, probably through regula-
tion of VEGF expression [9]. However, LA-NSCLC
accounts for a significant proportion of lung cancer, and
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with prognosis within this particular population.
Previous studies primarily focused on three common
functional single nucleotide polymorphisms of the VEGF
gene, including the -460 T > C, -634 G > C (also
assigned as +405 G > C) and +936 C > T (minor allele
frequency = 0.422, 0.431 and 0.222 in Caucasians,
respectively, according to the Hapmap database). The
-460 T > C SNP is located in the promoter region and
may influence the promoter activity [10]; the -634 G >
C SNP lies within the 5′-untranslated region and may
affect the transcriptional factor binding affinity [11]; the
+936 C > T SNP is located in the 3′-untranslated region
and has been associated with lower VEGF plasma levels
[12]. In the present study, we evaluated the association
of these three potentially functional VEGF SNPs (i.e.,
-460 T > C, -634 G > C [also assigned as +405 G > C]
a n d+ 9 3 6C>T )w i t ho v e r a l ls u r v i v a l( O S )o fL A -
NSCLC patients.
Methods
Study populations
Clinical data were derived from a large dataset of 576
NSCLC patients established at The University of Texas
M. D. Anderson Cancer Center (Houston, TX), in
which patients were recruited and histologically con-
firmed between Oct. 1998 and Nov. 2006. Details of this
study population have been described previously [13].
Briefly, this analysis consisted of 124 Caucasian patients
with stage IIIa or IIIb NSCLC according to the TNM
staging system, a relatively homogenous group that was
treated by chemoradiotherapy. Those patients who had
surgical resection, or had been treated elsewhere before
coming to M. D. Anderson were excluded from the ana-
lysis. The study protocol was approved by the M. D.
Anderson Cancer Center institutional review board and
informed consents were waived. We complied with
Health Insurance Portability and Accountability Act
(HIPAA) regulations.
Genotyping
Genomic DNA was extracted from the buffy coat frac-
tion of each blood sample by using a Blood Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions. DNA purity and concentrations were deter-
mined by spectrophotometric measurement of absor-
bance at 260 and 280 nm by UV spectrophotometer.
The selected three VEGF SNPs (-460 T > C/rs833061,
-634 G > C/rs2010963, and +936 C > T/rs3025039)
were genotyped using the polymerase chain reaction
(PCR) -restriction fragment length polymorphism
(RFLP) method. The PCR primers used for -460 T > C,
-634 G > C, and +936 C > T polymorphisms were
5′-CTCTTTAGCCAGAGCCGGGG-3′ (forward) and
5′-TGGCCTTCTCCCCGCTCCGAC-3′ (reverse); 5′-CG
ACGGCTTGGGGAGATTGC-3′ (forward) and 5′-GGG
CGGTGTCTGTCTGTCTG-3′ (reverse); and 5′-AGGG
TTCGGGAACCAGATC-3′ (forward) and 5′-CTCGG
TGATTTAGCAGCAAG-3′ (reverse), respectively. The
following PCR conditions were performed: one cycle at
95°C for 5 min; 35 cycles of 95°C for 30 s, 60°C for 30 s,
and 72°C for 45 s; and a final extension at 72°C for 10
min. The PCR products were studied after digestion
with BsaHI, BsmFI, and NlaIII restriction enzymes.
Genotypes of these VEGF SNPs were determined as pre-
viously reported [14]. For the PCR-RFLP-based genotyp-
ing assay, two research assistants independently read the
gel pictures, and the genotyping was repeated if there
was a disagreement of the result. We selected 10% of
the samples for replication, and the results were 100%
concordant.
Statistical analysis
The two-sided c
2 and Student t tests were performed to
determine any statistically significant differences in the
distributions of the VEGF genotypes by the demographic
variables and clinical features. We used the Kaplan-
Meier estimates to evaluate OS among three genotype
groups, and the log-rank test to test for equality of the
survival distributions. We conducted univariate analysis
and used multivariate Cox proportional hazard models
to estimate the effect of each SNP on survival with or
without other confounding factors. Haplotype frequen-
cies and individual haplotypes were generated using SAS
PROC HAPLOTYPE. The associations between haplo-
type and overall survival (OS) were determined using a
dominant genetic model to preserve statistical power.
All analyses were performed using SAS software (version
9.1; SAS Institute, Cary, NC).
Results
Population characteristics
Clinical and pathological characteristics of the patients
included in current study are shown in Table 1. Among
the 124 patients, there were 67 males (54%) and 57
females (46%), whose ages ranged from 35 to 88 years.
There were 40 (32.3%) adenocarcinoma, 38 (31.6%)
squamous cell carcinoma and 46 (37.1%) large cell carci-
noma. All patients received radiotherapy, delivered as
1.8 to 2 Gy per fraction once a day with a total median
radiation dose of 66 Gy (ranging between 50 and
72 Gy). A number of 112 (90.3%) patients also received
platinum plus taxane or etoposide-based chemotherapy.
At the end of follow-up, 92 (74.2%) patients died, and
the MST was 17 months (ranging between 1 and
97 months) in the overall study subjects.
To determine if there was any confounding factor
influencing patients’ death or survival time, we
Guan et al. BMC Cancer 2010, 10:431
http://www.biomedcentral.com/1471-2407/10/431
Page 2 of 9performed the chi-square test and univariate analysis of
Log-rank test for the relationship of death number and
OS with clinicopathologic characteristics. We did not
find any significant difference in the death distribution
by different clinicopathologic characteristics. However,
gender seemed to be a confounding factor of OS (MST:
17 months of male vs. 26 months of female, P = 0.046)
(Figure 1A), whereas age, smoking status, pack-year, his-
tology, application of chemotherapy, and radiation dose
did not. Notably, Karnofsky’s performance scores (KPS)
and clinical stage showed a marginally significant asso-
ciation with OS (P =0 . 0 6 7a n dP =0 . 0 8 8 )( F i g u r e1 B
and 1C), suggesting they might be additional confound-
ing factors required for control.
VEGF genotypes and NSCLC survival
The representative PCR-based restriction analyses for
the VEGF -460 T > C, -634 G > C, and +936 C > T
polymorphisms were shown in Figure 2. The genotype
distributions of the three VEGF SNPs and the associa-
tion with OS are summarized in Table 2. In all patient,
the -460 CT genotype (n = 67) was associated with a
significantly increased OS (crude hazard ratio [HR] =
0.60; 95% confidence interval [CI], 0.37-0.95, P = 0.031),
compared with the VEGF -460 TT genotype (n = 33).
After a multivariate adjustment with age, sex, smoking
status, tumor histology, KPS score, tumor stage, history
of chemotherapy, and radiation dose, the HR remained
statistically significant (adjusted HR = 0.56; 95% CI,
0.34-0.90, P = 0.018; Table 2). Although the homozy-
gous CC genotype showed a tendency favoring increased
OS, there was no statistical significance, probably
because of a reduced detecting power resulting from
small sample size (n = 24). Therefore, we combined the
CT and CC genotypes for additional analysis. Under this
dominant genetic model, the combined -460 CT/CC
Table 1 Characteristics of the study population (n = 124) and overall survival
Characteristics No. of Patients (%) No. of Deaths (%)* P
† MST (95% CI, month) P
‡
Age 0.456 0.468
≤ 60 years 55 (44.4) 39 (70.9) 21.0 (13.0-32.0)
> 60 years 69 (56.6) 53 (76.8) 18.0 (13.0-26.0)
Gender 0.175 0.046
Female 57 (46.0) 39 (68.4) 26.0 (17.0-38.0)
Male 67 (54.0) 53 (79.1) 17.0 (12.0-22.0)
Smoke 0.752 0.679
Ever 114 (91.9) 85 (74.6) 20.0 (16.0-26.0)
Never 10 (8.1) 7 (70.0) 16.0 (11.0-18.0)
Pack -year 0.542 0.861
≤ 40 60 (48.4) 46 (75.0) 19.0 (14.0-29.0)
> 40 64 (51.6) 46 (73.0) 20.0 (13.0-29.0)
Histology 0.828 0.632
Adenocarcinoma 40 (32.3) 31 (77.5) 20.0 (17.0-31.0)
Squamous cell 38 (31.6) 28 (73.7) 16.0 (12.0-25.0)
Others 46 (37.1) 33 (71.7) 24.0 (13.0-36.0)
KPS 0.175 0.067
90-100 38 (30.7) 24 (66.2) 22.0 (16.0-39.0)
80 67 (54.0) 53 (79.1) 20.0 (14.0-27.0)
< 80 19 (15.3) 15 (79.0) 13.0 (8.0-29.0)
Stage 0.057 0.088
IIIa 52 (41.9) 34 (65.4) 20.0 (16.0-39.0)
IIIb 72 (58.1) 58 (80.6) 17.0 (13.0-23.0)
Chemotherapy 0.186 0.766
Yes 112 (90.3) 85 (75.9) 20.0 (16.0-26.0)
No 12 (9.7) 7 (58.3) 17.0 (11.0-44.0)
Radiotherapy dose 0.360 0.857
< 70Gy 59 (47.6) 46 (78.0) 21.0 (16.0-33.0)
≥ 70Gy 65 (52.4) 46 (70.8) 17.0 (12.0-24.0)
Abbreviations: MST, median survival time.
* Percentage of deaths in each stratum.
† Chi -square test for difference in the distribution of deaths.
‡ Log-rank test for survival time in the univariate analysis.
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unadjusted Log-rank test.
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Page 4 of 9variant genotypes (n = 91) were associated significantly
with improved OS (adjusted HR = 0.58; 95% CI = 0.37-
0.92, P = 0.022) (Figure 3A), compared with the VEGF
-460 TT genotype (n = 33). For the other two VEGF
SNPs -634 G > C and +936 C > T, we repeated the ana-
lyses but did not find any significant associations under
either the additive model or dominant model (Table 2
and Figure 3B and 3C).
To determine if the influence of VEGF SNPs was sub-
stantially affected by tumor stage, we further made stra-
tified analyses by separating the patients into two
subgroups, stages IIIa and IIIb. We found that none of
the three SNPs showed significant influence on OS,
except for the CT genotype of VEGF -460 T > C SNP,
which was marginally associated with increased OS in
NSCLC patients of stage IIIb (adjusted HR = 0.56; 95%
CI, 0.30-1.05, P = 0.071 and other data not shown).
VEGF haplotypes and NSCLC survival
We further explored the haplotypes to evaluate the
combined effect of the three polymorphisms on NSCLC
survivals. There were five haplotypes with frequencies >
5% among all cases, and other less common haplotypes
(frequencies < 5%) were combined into one group. The
five most common haplotypes in the patients were
-460C/-634G/+936C (C-G-C), T-C-C, T-G-C, T-C-T,
and C-C-C with the respective frequencies of 38.8%,
23.8%, 17.7%, 8.8% and 5.4%, which were similar to
those reported in the other Caucasian populations [15].
However, we did not find a significant impact on OS
from the other haplotypes, compared to the most com-
mon C-G-C haplotype (data not shown).
Discussion
Several studies have reported the association between
VEGF polymorphisms and progress and survival of dif-
ferent cancers [16-19], but no study has investigated the
association between the VEGF polymorphisms and
LA-NSCLC patients’ s u r v i v a lt od a t e .T or e d u c e
Figure 2 PCR-based restriction analysis of the VEGF SNPs
shown on agarose electrophoresis.
Table 2 Association between VEGF genotypes and overall survival
Genotypes Case No. Deaths No. (%)* MST (95% CI, month) Crude HR (95% CI) P
† Adjusted HR (95% CI) P
‡
VEGF -460T > C (rs833061)
TT 33 28 (84.9) 16.0 (11.0-25.0) 1.00 1.00
CT 67 47 (70.2) 21.0 (17.0-32.0) 0.60 (0.37-0.95) 0.031 0.56 (0.34-0.90) 0.018
CC 24 17 (70.8) 27.0 (10.0-36.0) 0.75 (0.41-1.37) 0.347 0.67 (0.36-1.26) 0.212
CT+CC 91 64 (70.3) 21.0 (17.0-31.0) 0.63 (0.40-0.99) 0.043 0.58 (0.37-0.92) 0.022
VEGF -634G > C (rs2010963)
GG 57 40 (70.2) 23.0 (16.0-36.0) 1.00 1.00
CG 41 34 (82.9) 17.0 (13.0-25.0) 1.20 (0.76-1.90) 0.440 1.17 (0.74-1.88) 0.502
CC 26 18 (69.2) 12.0 (9.0-29.0) 1.25 (0.71-2.18) 0.436 1.28 (0.72-2.28) 0.399
CG+CC 67 52 (76.1) 17.0 (12.0-24.0) 1.22 (0.80-1.84) 0.356 1.21 (0.79-1.84) 0.379
VEGF +936C > T (rs3025039)
CC 92 68 (73.9) 21.0 (16.0-29.0) 1.00 1.00
CT 30 22 (73.3) 17.0 (11.0-29.0) 1.08 (0.67-1.75) 0.742 1.00 (0.60-1.66) 0.992
TT 2 2 (100) 14.5 (9.0-20.0) 2.14 (0.52-8.80) 0.291 1.95 (0.46-8.29) 0.367
CT+TT 32 24 (75.0) 17.0 (11.0-28.0) 1.13 (0.71-1.80) 0.606 1.05 (0.65-1.71) 0.839
Abbreviation: MST, median survival time.
* Percentage of deaths in each stratum
† P values were calculated using the log-rank test in the univariate analysis.
‡ P values were obtained from the Cox hazards model with adjustment for age, sex, smoking status, tumor histology, KPS score, tumor stage, application of
chemotherapy and radiotherapy dose.
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smoking status, tumor histology, KPS score, tumor stage, use of chemotherapy and radiotherapy dose.
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ciation, we limited our study subjects to a group of 124
Caucasian patients with homogenous stage IIIa and IIIb
NSCLC, who received well-documented definitive che-
moradiotherapy as previously described [13]. We found
that the VEGF - 460 C variant genotypes were asso-
ciated with a significantly improved OS, compared with
the VEGF -460 TT genotype.
To give a comprehensive view of the association
between VEGF genotypes and the prognosis of different
cancer types, we summarized the published data in
Table 3. Most of these studies confirmed an influence of
VEGF SNPs on the overall survival of cancer patients.
However, these studies differed substantially in their
conclusions. Even for the same VEGF SNP, different
risk allele was reported. Different ethnic populations
might be one rational reason for the inconsistent results.
A n o t h e rp o s s i b l ee x p l a n a t i o nm a yb et h a tt h ee f f e c t so f
VEGF are tumor-specific. The interaction of different
therapeutic strategies with VEGF genotypes may also
contribute to the diverse clinical outcomes. In NSCLC,
the three studies (including ours) were not consistent in
the VEGF risk alleles, suggesting that a further investiga-
tion was warranted. For example, Masago et al. reported
an association between -460 C allele and a poorer survi-
val of advanced NSCLC in Japanese patients [20], which
was opposite to our findings in Caucasian patients.
Numerous factors could have played a role in the ethnic
discrepancy, including gene-gene interaction from differ-
ent genetic background and gene-environmental interac-
tion from different lifestyles. Even in the same ethnicity
of Caucasians, the study by Heist et al. failed to find any
significant association between -460 C allele and survival
in 462 early-stage NSCLC patients, most of whom were
surgically resected [9]. In that study, there were only
32 patients (7%) receiving radiation and three patients
(0.6%) treated with chemotherapy. In contrast, the 124
LA-NSCLC patients of current study all received radio-
therapy, and carriers of the C allele of -460 T > C poly-
morphism were found to benefit from radiotherapy.
These findings, once validated in larger studies, will
guide tailored therapeutics for individual patients.
It is not clear how the VEGF -460 C allele contri-
butes to a better survival in LA-NSCLC patients. A
previous in vitro study indicated that the T allele of
the VEGF -460 T > C polymorphism located in the
promoter of the VEGF gene was associated with a
decreased VEGF promoter activity [10]. Hence, the
VEGF -460 C allele may be associated with an
increased VEGF expression, which would promote
tumor angiogenesis. However, the majority of NSCLC
patients included in the current study received che-
motherapy in addition to radiotherapy (112 out of
124). It is possible that the increased tumor vascula-
ture may enhance radiotherapy efficacy through inhi-
biting tumor radioresistance from radiation-induced
hypoxia, or facilitate the delivery of chemotherapeutic
agents to the tumor site and may have led to enhanced
synergistic effect with radiotherapy. Or, the VEGF -460
C allele has some additional unknown biological func-
tions, besides regulation of mRNA expression. Further
mechanistic studies are required to clarify this issue.
Table 3 Summary of the influence of VEGF SNPs on cancer OS
First
author
Year Cancer Country Ethnicity SNPs No. Risk allele
Guan
(Current)
2010 LA-NSCLC USA Caucasian -460T > C, -634G > C, and 936C > T 124 T for -460T > C
Formento
[23]
2009 Head&neck France Caucasian -460T > C, -634G > C, and 936C > T 49 None
Masago
[20]
2009 Advanced
NSCLC
Japan Asian -460T > C, -1154G > A, -2578C > A,
405G > C, and 936C > T
126 C for -460T > C, A for -1154G > A, and A for
-2578C > A
Dassoulas
[24]
2009 Colorectum Greece Caucasian -460T > C, -634G > C, -1154G > A,
-2578C > A, and 936C > T
312 T for -460T > C, G for -634G > C, C for -2578C
> A, and C for 936C > T
Bradbury
[25]
2009 Esophagus Canada Caucasian -460T > C, 405G > C, and 936C > T 361 C for 936C > T
Heist [9] 2008 Early
NSCLC
USA Caucasian -460T > C, 405G > C, and 936C > T 462 G for 405G > C and C for 936C > T
Kim [16] 2008 Colorectum Korea Asian -634G > C, -2578C > A, and 936C > T 445 G for -634G > C and T for 936C > T
Kim [26] 2007 Stomach Korea Asian -116G > A, -460T > C, 405G > C, and
936C > T
503 C for -460T > C and T for 936C > T
Kawai [27] 2007 Renal cell Japan Asian -634G > C, -2578C > A, and -1154G > A 213 C for -2578C > A
Hefler [17] 2007 Ovarian Austria Caucasian -634G > C, -1154G > A, and -2578C > A 563 None
Tzanakis
[28]
2006 Stomach Greece Caucasian -634G > C, -2578C > A, -1154G > A,
and 936C > T
100 C for -634G > C
Lu [19] 2005 Breast China Asian -460T > C, 405G > C, and 936C > T 1119 C for -460T > C, and G for 405G > C
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with stage IIIa and IIIb only, who received radiotherapy
mostly in the range of 60-70 Gy with detailed OS data.
However, there are several limitations. First, the study
could not address the mechanism of how the VEGF poly-
morphisms influence the survival outcomes of lung can-
cer patients. Previous study demonstrated a good
correlation between TC/CC genotypes of the VEGF -460
T > C polymorphism and increased serum VEGF levels
in colorectal cancer patients [21]. An increased serum
VEGF expression was also observed in ovarian cancer
patients carrying -634 C allele [22]. We are collecting
related data to determine if there is such correlation
between the VEGF polymorphisms and the VEGF protein
levels in NSCLC patients. Secondly, we only included
three common functional, promoter VEGF SNPs, which
is far from comprehensive. Indeed, the VEGF gene is
highly polymorphic with at least 140 variants reported to
date http://www.ncbi.nlm.nih.gov/SNP/. Some important
functional SNPs may be missed or the observed associa-
tion may result from genetic linkages with other untyped
SNPs. Thirdly, our sample size is not big enough to allow
evaluation of interactions between the studied poly-
morphisms and dose of radiation therapy. For the same
reason, there appeared a wide confidence interval in our
stratified analyses by tumor stage and the significance
was lost due to the reduced statistical power. Therefore,
a complete investigation of tagging SNPs in larger sam-
ples may be necessary in future studies.
Conclusion
In summary, we found that the VEGF -460 C allele may
be associated with a better survival of LA-NSCLC
patients treated with chemoradiotherapy. Future pro-
spective studies with large sample sizes and better study
designs are required to confirm our findings.
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